The WHO criteria for co-trimoxazole prophylaxis among PLHIV are CD4 count ≤350 cells/mm3 or clinical stage 3 or 4, or lifelong co-trimoxazole for any CD4 count in settings with a high prevalence of malaria or bacterial infections. This evidence concerns the gene CD4 and malaria.